Track Trillium Therapeutics's long-term debt ($340K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2021), TRIL shows a long-term debt of $340K. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, TRIL's long-term debt is now $340K (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Trillium Therapeutics is outperforming or lagging.
Tracking TRIL's long-term debt over time shows whether Trillium Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $340K In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Trillium Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $340K) with ownership activity and broader fundamentals.
Trillium Therapeutics's long-term debt is $340K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.